Shattuck Labs Inc
STTK
Get informed when a big investor buys or sells
+ FollowMarket Cap$670.56M
Close$
$0.45
93.9% downside
Current Fair Value
93.9% downsideOvervalued by 93.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $670.56 Million |
|---|---|
| Enterprise Value | $609.94 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.7 |
| Beta | 1.11 |
| Outstanding Shares | 129,779,297 |
Return
| Return on Equity | -24.90% |
|---|---|
| Return on Assets | -23.82% |
| Return on Invested Capital | -25.69% |
Valuation & Multiples
| P/E Ratio | -14.55 |
|---|---|
| PEG | -67.28 |
| Price to Sales | - |
| Price to Book Ratio | 7.32 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -11.15 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 49.96%▲ 9.46% |
|---|---|
| Total Invested | $360.44M▲ 135.01% |
| Investors Holding | 83▲ 20.00% |
ESG Score
No data
About Shattuck Labs Inc
59 employeesShattuck Labs, Inc. operates as a clinical-stage biotechnology company . The Company focuses on developing a novel class of biologic medicines for the treatment of cancer and autoimmune diseases. Shattuck Labs serves customers in the State of Texas.